Astellas Acquires Xyphos Biosciences for ~$665M

 Astellas Acquires Xyphos Biosciences for ~$665M

Astellas Acquires Xyphos Biosciences for ~$665M

Shots:

  • Xyphos to receive $120 upfront, up to $545M as development milestones, making a total deal value as ~$665M. Xyphos will act as a wholly own subsidiary of Astellas
  • The focus of the acquisition is to bolster Astellas’ immuno-oncology pipeline with the addition of Xyphos’ ACCEL (Advanced Cellular Control through Engineered Ligands) technology platform
  • Xyphos’ platform directs cells of the immune system to target single/ multiple tumor antigens while controlling the immune cell proliferation and endurance. Xyphos’s molecules utilizes its CAR technology which is based on a modification to NKG2D with the expected initiation of clinical study for its first CART cell therapy in 2021

Click here to­ read full press release/ article | Ref: Astellas | Image: Xyphos

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post